Safety review update of Revlimid and risk of developing new types of malignancies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

There is an increased risk of second primary malignancies in patients with newly-diagnosed multiple myeloma who received Revlimid (lenalidomide), according to FDA.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

An interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma, showed that the trial met its primary endpoint of progression-free survival at a prespecified interim analysis and was unblinded early based on the recommendation by an Independent Data Monitoring Committee.

Login